What is the treatment for subconjunctival hemorrhage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Subconjunctival Hemorrhage

Subconjunctival hemorrhage requires no specific treatment as it typically resolves spontaneously within 1-2 weeks without intervention. 1

Understanding Subconjunctival Hemorrhage

Subconjunctival hemorrhage is a common clinical presentation characterized by blood accumulation between the conjunctiva and sclera. While it appears alarming to patients due to its bright red appearance, it is generally benign and self-limiting.

Management Approach

Primary Treatment

  • Observation: The mainstay of treatment is observation and reassurance, as most cases resolve spontaneously within 1-2 weeks
  • Artificial tears: May be used if mild irritation is present
  • Cold compresses: Can be applied in the first 24-48 hours to reduce discomfort

When to Consider Additional Evaluation

Additional evaluation should be considered in cases with:

  • Recurrent or bilateral hemorrhages
  • Severe or extensive bleeding
  • Associated trauma
  • Patients on anticoagulation therapy
  • Systemic symptoms suggesting underlying disease

Special Considerations

Traumatic Subconjunctival Hemorrhage

  • Requires thorough evaluation for associated ocular injuries
  • Visual acuity assessment is crucial - reduced vision (< 20/40) significantly increases the probability of additional ocular damage 2
  • Complete eye examination to rule out globe rupture or other injuries

Medication-Related Hemorrhage

  • Patients on anticoagulants may experience more frequent or severe subconjunctival hemorrhages 3
  • No need to discontinue anticoagulation therapy for isolated subconjunctival hemorrhage
  • Consider consulting with the prescribing physician if hemorrhages are recurrent or extensive

Systemic Disease Considerations

  • Recurrent spontaneous subconjunctival hemorrhages may indicate underlying systemic disorders such as:
    • Hypertension
    • Blood dyscrasias
    • Thrombocytopenia
    • Coagulopathies
  • Complete blood count and coagulation studies may be warranted in recurrent cases 4

Patient Education

  • Reassure patients about the benign nature and self-limiting course
  • Explain that the blood will gradually change color (similar to a bruise) before completely resolving
  • Advise against eye rubbing
  • Instruct patients to return if:
    • Vision changes occur
    • Pain develops
    • Hemorrhage doesn't resolve within 2-3 weeks
    • New hemorrhages develop frequently

Prevention in High-Risk Settings

For patients undergoing procedures with high risk of subconjunctival hemorrhage (e.g., intravitreal injections):

  • Topical oxymetazoline applied 30 minutes before the procedure can reduce the incidence of subconjunctival hemorrhage 5

Clinical Pitfalls to Avoid

  • Overlooking trauma as a cause of subconjunctival hemorrhage
  • Missing associated ocular injuries in traumatic cases
  • Failing to investigate recurrent or bilateral hemorrhages
  • Not considering systemic causes in spontaneous, recurrent cases
  • Unnecessary treatment with antibiotics or other medications that provide no benefit

Remember that while most subconjunctival hemorrhages are benign, they can occasionally be the first presenting sign of a serious systemic condition such as idiopathic thrombocytopenic purpura or other blood disorders 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Subconjunctival and external hemorrhage secondary to oral anticoagulation.

Journal of the American Optometric Association, 1990

Research

Oxymetazoline: reduction of subconjunctival hemorrhage incidence after intravitreal injections.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.